CLNN Clene Inc.

USD 0.43 0.00 0.212214
Icon

Clene Inc. (CLNN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.425

+0.00 (+0.21)%

USD 0.06B

0.27M

N/A

USD 3.00 (+605.88%)

Icon

CLNN

Clene Inc. (USD)
COMMON STOCK | NSD
USD 0.43
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.06B

USD 3.00 (+605.88%)

USD 0.43

Clene Inc. (CLNN) Stock Forecast

N/A

Based on the Clene Inc. stock forecast from 0 analysts, the average analyst target price for Clene Inc. is not available over the next 12 months. Clene Inc.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Clene Inc. is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Clene Inc.’s stock price was USD 0.425. Clene Inc.’s stock price has changed by +6.25% over the past week, +0.00% over the past month and -63.04% over the last year.

No recent analyst target price found for Clene Inc.
No recent average analyst rating found for Clene Inc.

Company Overview Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registra...Read More

https://clene.com

6550 South Millrock Drive, Salt Lake City, UT, United States, 84121

75

December

USD

USA

Adjusted Closing Price for Clene Inc. (CLNN)

Loading...

Unadjusted Closing Price for Clene Inc. (CLNN)

Loading...

Share Trading Volume for Clene Inc. Shares

Loading...

Compare Performance of Clene Inc. Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CLNN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Clene Inc. (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.14 (-0.27%) USD107.38B 29.93 21.06

ETFs Containing CLNN

Symbol Name CLNN's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Clene Inc. (CLNN) Stock

Stock Target Advisor's fundamental analysis for Clene Inc.'s stock is Bearish.

Unfortunately we do not have enough data on CLNN's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on CLNN's stock to indicate what its average analyst target is.

CLNN stock's Price/Earning ratio is 4.41. Our analysis grades CLNN stock's Price / Earning ratio at F. This means that CLNN stock's Price/Earning ratio is above 44.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange. Based on this CLNN may be fairly valued for its sector

The last closing price of CLNN's stock was USD 0.43.

The most recent market capitalization for CLNN is USD 0.06B.

Unfortunately we do not have enough analyst data on CLNN's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Clene Inc.'s stock.

As per our most recent records Clene Inc. has 75 Employees.

Clene Inc.'s registered address is 6550 South Millrock Drive, Salt Lake City, UT, United States, 84121. You can get more information about it from Clene Inc.'s website at https://clene.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...